The Infrastructure Behind Bringing New Therapies to Market: A Conversation with Melissa Marlowe

The promise of cell and gene therapy is extraordinary. But between a scientific breakthrough and a patient receiving a potentially life-changing treatment lies one of the most complex, precise, and largely invisible networks in healthcare.Recorded live from the BIO International Convention, host Tom Osha sits down with Melissa Marlow, Vice President of Clinical Services and Biotherapies Lab at Vitalant, to explore the infrastructure behind advanced cell therapies and why that infrastructure is critical to expanding patient access.With roots stretching back to a Phoenix blood bank founded more than 80 years ago, Vitalant has built a national network capable of supporting the collection, handling, storage, and delivery of increasingly complex therapies. Melissa takes us behind the scenes of that network, where cells may need to be stored below -150 degrees Celsius, timing is measured in critical windows, and a single patient therapy can touch more than 100 people on its journey from collection to manufacturing and back to the patient.Unlike a traditional pharmaceutical product, many of today's cell therapies are autologous, created from a patient's own cells specifically for that patient. There is no replacement batch sitting on a shelf. Every product is truly one of a kind.Tom and Melissa also discuss the next frontier: moving therapies like CAR-T beyond treatments of last resort and expanding access to patients outside the nation's largest academic medical centers.It's a conversation about science, logistics, culture, and the remarkable human infrastructure required to turn breakthrough medicine into patient care.